244 related articles for article (PubMed ID: 26314842)
1. Host genotype and tumor phenotype of chemokine decoy receptors integrally affect breast cancer relapse.
Yu KD; Wang X; Yang C; Zeng XH; Shao ZM
Oncotarget; 2015 Sep; 6(28):26519-27. PubMed ID: 26314842
[TBL] [Abstract][Full Text] [Related]
2. Effect of genetic variants in two chemokine decoy receptor genes, DARC and CCBP2, on metastatic potential of breast cancer.
Yang C; Yu KD; Xu WH; Chen AX; Fan L; Ou ZL; Shao ZM
PLoS One; 2013; 8(11):e78901. PubMed ID: 24260134
[TBL] [Abstract][Full Text] [Related]
3. Effect of functional genetic variants in chemokine decoy receptors on the recurrence risk of breast cancer.
Li DD; Yang C; Shao ZM; Yu KD
Cancer Med; 2018 Nov; 7(11):5497-5504. PubMed ID: 30358125
[TBL] [Abstract][Full Text] [Related]
4. Atypical chemokine receptors predict lymph node metastasis and prognosis in patients with cervical squamous cell cancer.
Hou T; Liang D; Xu L; Huang X; Huang Y; Zhang Y
Gynecol Oncol; 2013 Jul; 130(1):181-7. PubMed ID: 23603371
[TBL] [Abstract][Full Text] [Related]
5. High casein kinase 1 epsilon levels are correlated with better prognosis in subsets of patients with breast cancer.
Lopez-Guerra JL; Verdugo-Sivianes EM; Otero-Albiol D; Vieites B; Ortiz-Gordillo MJ; De León JM; Praena-Fernandez JM; Marin JJ; Carnero A
Oncotarget; 2015 Oct; 6(30):30343-56. PubMed ID: 26327509
[TBL] [Abstract][Full Text] [Related]
6. [Duffy antigen receptor for chemokines attenuates breast cancer growth and metastasis: an experiment with nude mice].
Wang J; Ou ZL; Hou YF; Luo JM; Chen Y; Zhou J; Shen ZZ; Ding J; Shao ZM
Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(29):2033-7. PubMed ID: 16313795
[TBL] [Abstract][Full Text] [Related]
7. HER2 exon 27 mutations predict worse survival of breast cancer patients, especially in HER2-negative patients.
Si P; Chen T; Fang B; Yao J; Liu G; Chen H; Zhai B; Li W
Cancer Med; 2017 Dec; 6(12):2832-2839. PubMed ID: 29072371
[TBL] [Abstract][Full Text] [Related]
8. Chemokine decoy receptor d6 plays a negative role in human breast cancer.
Wu FY; Ou ZL; Feng LY; Luo JM; Wang LP; Shen ZZ; Shao ZM
Mol Cancer Res; 2008 Aug; 6(8):1276-88. PubMed ID: 18708360
[TBL] [Abstract][Full Text] [Related]
9. Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness.
Snoussi K; Mahfoudh W; Bouaouina N; Fekih M; Khairi H; Helal AN; Chouchane L
BMC Cancer; 2010 Jun; 10():283. PubMed ID: 20540789
[TBL] [Abstract][Full Text] [Related]
10. S4646 polymorphism in CYP19A1 gene is associated with the efficacy of hormone therapy in early breast cancer.
Shao X; Cai J; Zheng Y; Wang J; Feng J; Huang Y; Shi L; Chen Z; Guo Y; Wang X
Int J Clin Exp Pathol; 2015; 8(5):5309-17. PubMed ID: 26191232
[TBL] [Abstract][Full Text] [Related]
11. Coexpression of atypical chemokine binders (ACBs) in breast cancer predicts better outcomes.
Zeng XH; Ou ZL; Yu KD; Feng LY; Yin WJ; Li J; Shen ZZ; Shao ZM
Breast Cancer Res Treat; 2011 Feb; 125(3):715-27. PubMed ID: 20369284
[TBL] [Abstract][Full Text] [Related]
12. Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential.
Wang J; Ou ZL; Hou YF; Luo JM; Shen ZZ; Ding J; Shao ZM
Oncogene; 2006 Nov; 25(54):7201-11. PubMed ID: 16785997
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory mediators in breast cancer: coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition.
Soria G; Ofri-Shahak M; Haas I; Yaal-Hahoshen N; Leider-Trejo L; Leibovich-Rivkin T; Weitzenfeld P; Meshel T; Shabtai E; Gutman M; Ben-Baruch A
BMC Cancer; 2011 Apr; 11():130. PubMed ID: 21486440
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of long noncoding RNA HOTTIP on clinical outcomes in breast cancer.
Yang Y; Qian J; Xiang Y; Chen Y; Qu J
Oncotarget; 2017 Jan; 8(4):6833-6844. PubMed ID: 28036281
[TBL] [Abstract][Full Text] [Related]
15. A Duffy antigen receptor for chemokines (DARC) polymorphism that determines pro-fibrotic chemokine serum concentrations is not directly associated with severity of hepatitis C infection.
Lettow I; Berres ML; Schmitz P; Müller T; Berg T; Neumann UP; Trautwein C; Wasmuth HE
Hum Immunol; 2011 Mar; 72(3):273-7. PubMed ID: 21156192
[TBL] [Abstract][Full Text] [Related]
16. Single nucleotide polymorphism rs13042395 in the SLC52A3 gene as a biomarker for regional lymph node metastasis and relapse-free survival of esophageal squamous cell carcinoma patients.
Tan HZ; Wu ZY; Wu JY; Long L; Jiao JW; Peng YH; Xu YW; Li SS; Wang W; Zhang JJ; Li EM; Xu LY
BMC Cancer; 2016 Jul; 16():560. PubMed ID: 27472962
[TBL] [Abstract][Full Text] [Related]
17. Expression of DARC, CXCR3 and CCR5 in giant cell arteritis.
Brühl H; Vielhauer V; Weiss M; Mack M; Schlöndorff D; Segerer S
Rheumatology (Oxford); 2005 Mar; 44(3):309-13. PubMed ID: 15572394
[TBL] [Abstract][Full Text] [Related]
18. In situ binding assay for studying chemokine interactions with endothelial cells.
Rot A
J Immunol Methods; 2003 Feb; 273(1-2):63-71. PubMed ID: 12535798
[TBL] [Abstract][Full Text] [Related]
19. A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome.
Hachim IY; Shams A; Lebrun JJ; Ali S
Hum Pathol; 2016 Jul; 53():142-52. PubMed ID: 26980025
[TBL] [Abstract][Full Text] [Related]
20. Absence of multiple atypical chemokine binders (ACBs) and the presence of VEGF and MMP-9 predict axillary lymph node metastasis in early breast carcinomas.
Zeng XH; Ou ZL; Yu KD; Feng LY; Yin WJ; Li J; Shen ZZ; Shao ZM
Med Oncol; 2014 Sep; 31(9):145. PubMed ID: 25097078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
